Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Shouldn’t pharmacovigilance be less painful?

Posted on May 26th, 2017 by in Pharmacovigilance

PV white board

Even with advanced information technologies, too many companies and pharmacovigilance practitioners are still living with the pain of having to rely on ineffective and outdated systems and processes. (more…)

The Role of Scientific Literature in Pharmacovigilance: Challenges and Solutions

Posted on May 6th, 2016 by in Pharmacovigilance

Medical-Literature

After our recent webinar, Elsevier received several questions from attendees. During the next few weeks, we will discuss some of the questions in more detail.  (more…)

Data Transparency in Pharmacovigilance: European regulators give increased access to adverse drug reactions

Posted on March 16th, 2016 by in Pharma R&D

On 17 December 2015, the European Medicines Agency (EMA) adopted the revised policy on access to Eudravigilance. According to the press release, the EMA will give increased access to reports of adverse reactions (more…)

Validation: The importance of search formulas in Literature Monitoring

Posted on February 29th, 2016 by in Pharmacovigilance

A reasonable number of Market Authorization Holders (MAHs) have no ready answer to justify why they use a specific search formula for each specific product when Audit or Inspection time comes: (more…)

  1. 1
  2. 2
  3. 3